- Home
- TXG
as 04-01-2025 4:00pm EST
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 1.3B | IPO Year: | 2019 |
| Target Price: | $20.00 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.54 - $37.74 | Next Earning Date: | 04-29-2025 |
| Revenue: | $610,785,000 | Revenue Growth: | -1.28% |
| Revenue Growth (this year): | 1.43% | Revenue Growth (next year): | 8.86% |
Stock Insider Trading Activity of 10x Genomics Inc. (TXG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saxonov Serge | TXG | Chief Executive Officer | Feb 28 '25 | Sell | $10.63 | 7,942 | $84,393.28 | 871,540 | |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 24 '25 | Sell | $11.07 | 5,092 | $56,346.04 | 871,540 | |
| Hindson Benjamin J. | TXG | See Remarks | Feb 24 '25 | Sell | $11.07 | 4,573 | $50,602.99 | 335,324 | |
| MATEO ALAN | TXG | Director | Feb 21 '25 | Buy | $11.14 | 40,000 | $445,572.00 | 61,691 |
Latest 10x Genomics Inc. News
TXG Breaking Stock News: Dive into TXG Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth
FastCompany
15 days ago
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
StockStory
22 days ago
2 Reasons to Sell TXG and 1 Stock to Buy Instead
PR Newswire
a month ago
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
StockStory
a month ago
1 Stock Under $50 on Our Watchlist and 2 to Ignore
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 02/26/2025
PR Newswire
a month ago
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
PR Newswire
a month ago
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
Compare TXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.